Journal
NATURE BIOTECHNOLOGY
Volume 31, Issue 5, Pages 426-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.2561
Keywords
-
Categories
Funding
- US National Institutes of Health (NIH) [MH087877, NS30800, EY019880]
- NIH [F31NS083354, T32GM008056]
- Case Western Reserve University School of Medicine
- New York Stem Cell Foundation
- Mt. Sinai Health Care Foundation
- Cytometry & Imaging Microscopy
- Gene Expression and Genotyping core facilities of the Case Comprehensive Cancer Center [P30CA043703]
Ask authors/readers for more resources
Cell-based therapies for myelin disorders, such as multiple sclerosis and leukodystrophies, require technologies to generate functional oligodendrocyte progenitor cells. Here we describe direct conversion of mouse embryonic and lung fibroblasts to induced oligodendrocyte progenitor cells (iOPCs) using sets of either eight or three defined transcription factors. iOPCs exhibit a bipolar morphology and global gene expression profile consistent with bona fide OPCs. They can be expanded in vitro for at least five passages while retaining the ability to differentiate into multiprocessed oligodendrocytes. When transplanted to hypomyelinated mice, iOPCs are capable of ensheathing host axons and generating compact myelin. Lineage conversion of somatic cells to expandable iOPCs provides a strategy to study the molecular control of oligodendrocyte lineage identity and may facilitate neurological disease modeling and autologous remyelinating therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available